NCT02681302 2026-04-03
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
Clinical Trials
120 trialsNCT04904302 2026-03-20
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04966676 2026-01-08
ATLAS
University Health Network, Toronto
Phase 2 Terminated
NCT03274258 2025-12-03
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT04057365 2025-08-13
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
Phase 2 Terminated
NCT04611126 2025-08-12
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT03547999 2025-07-22
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03815942 2025-06-25
ADVANCE
University of Oxford
Phase 1/2 Terminated
NCT02446860 2025-06-06
ADAPTeR
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT06003075 2025-04-30
Induction Chemo-Nivo in Unresectable Stage III NSCLC
University of Kentucky
Phase 2 Terminated
NCT03527264 2025-04-04
BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Brown University
Phase 2 Terminated
NCT04239040 2025-03-19
GVAX Plus Checkpoint Blockade in Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT06884683 2025-03-19
NivoMet
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Terminated
NCT03727061 2025-03-11
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT04901988 2025-02-27
DETECTION
The Christie NHS Foundation Trust
Phase 2/3 Terminated
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT04967196 2024-12-10
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Mayo Clinic
Phase 1 Terminated
NCT04375527 2024-12-04
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT03539198 2024-11-14
Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
Mayo Clinic
Terminated
NCT04270864 2024-10-18
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT04431635 2024-09-27
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT05200143 2024-09-19
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Providence Health & Services
Phase 2 Terminated
NCT03552380 2024-09-03
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04159896 2024-07-16
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT03631641 2024-07-01
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT02949843 2024-06-28
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Wake Forest University Health Sciences
Phase 2 Terminated
NCT05116917 2024-05-28
INFLUENCE
Herlev Hospital
Phase 2 Terminated
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT03562507 2024-05-20
ERICA
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02621515 2024-05-06
CA209-322
University Medical Center Groningen
Phase 2 Terminated
NCT04429321 2024-04-26
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT02978443 2024-04-04
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Georgetown University
Phase 2 Terminated
NCT02992964 2024-04-02
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
The Hospital for Sick Children
Phase 1/2 Terminated
NCT04610658 2024-04-02
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT04899921 2024-03-26
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03519308 2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03812562 2024-02-21
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
Northwestern University
Phase EARLY_PHASE1 Terminated
NCT03495713 2024-01-17
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated